Intravenous sildenafil in right ventricular dysfunction with pulmonary hypertension following a heart transplant
The objective of the present work is to describe the experience with intravenous (IV) sildenafil in heart transplant
(HT) patients with reactive pulmonary hypertension (PH) who developed right ventricular dysfunction (RVD) in
the immediate postoperative period. The first 5 patients who received IV sildenafil followinga HT are presented.
The HTs took place between March 2011 and September 2012 in patients aged 37 to 64 years; all patients were
male. Prior to the HT, mean pulmonary artery pressure (mPAP) was 32-56 mmHg. In all cases, the hemodynamic
study demonstrated PH reactivity (positive vasodilator test with nitric oxide). All 5 patients developed RVD with
hemodynamic instability immediately after the HT, despite the administration of nitric oxide from the time of
intubation prior to the implant, optimal medical treatment in all cases, and a ventricular assist in 2 cases. In all
patients, IV sildenafil was initiated at 10 mg/8 h for 48 h and was subsequently increased to 20 mg/8 h. in its oral
formulation until discharge from the hospital. The change in pulmonary pressure was assessed using a Swan-Ganz
catheter. Ventricular function was assessed using echocardiography. Length of stay in the Resuscitation Unit and
mid-term survival were also assessed.
Average time of extracorporeal circulation was 200 ± 110 min and organ ischemic time was 210 ± 95 min. All of the patients demonstrated pulmonary and systemic hemodynamic improvement, as well as recovery of right ventricular function after completing the treatment with IV sildenafil. The stay in the Resuscitation Unit lasted 3-25 days. All the patients were discharged from hospital with no mortality to date. Intravenous sildenafil improves right ventricle hemodynamics associated with pulmonary hypertension post-HT. Prophylactic prevention with this drug could be indicated for patients with reactive PH who are about to receive a transplant.
Cardiac transplant, PDE-5 inhibitor, Intravenous sildenafil, Pulmonary hypertension, Right ventricular dysfunction.
Financial support: None
Ignacio J. Sánchez Lázaro avenida Ausias March 2 esc 2, pta 15 46111 Rocafort Valencia, Spain email@example.com
Share this Article
Related Content In Hypertension
Atrial Fibrillation and Dementia
European Journal of Arrhythmia & Electrophysiology. 2020;6(1):10-6 DOI: https://doi.org/10.17925/EJAE.2020.6.1.10
Atrial fibrillation (AF) is one of the most common arrhythmias. It affected 33.5 million people worldwide in 2010, a number that is expected to double by 2050.1 AF prevalence increases with age, and approximately 25% of individuals aged 40 years or older will develop AF during their lifetime.2,3 Irrespective of age, AF incidence also increases with diabetes […]
Renal Denervation in High-risk Patients with Hypertension
Heart International. 2019;13(2):12-6 DOI: https://doi.org/10.17925/HI.2019.13.2.12
Hypertension is a global health problem, with an estimated 1.13 billion individuals affected.1 Patients with hypertension, especially when resistant to conventional therapy, are at high risk of sequelae, e.g., ischaemic heart disease, haemorrhagic and ischaemic stroke, cardiac failure, peripheral vascular disease and end-stage renal disease.2 Renal denervation (RD) is an emerging treatment modality which allows […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!